Maarten Ligtenberg, Flindr Therapeutics CEO

Dutch biotech at­tracts J&J sup­port for can­cer pipeline in $21M Se­ries A

Flindr Ther­a­peu­tics has se­cured €20 mil­lion ($21 mil­lion) in a Se­ries A raise aimed at ad­vanc­ing its lead pro­gram through an IND ap­pli­ca­tion and grow­ing its pipeline of small-mol­e­cule can­cer drugs.

The Dutch biotech’s lead drug can­di­date in­hibits RNF31, a pro­tein-sta­bi­liz­ing E3 ubiq­ui­tin lig­ase. The mech­a­nism had “high­ly promis­ing ac­tiv­i­ty” in pre­clin­i­cal ovar­i­an can­cer and B cell lym­phoma mod­els, Flindr said, adding it has iden­ti­fied bio­mark­ers that could help iden­ti­fy pa­tients most like­ly to re­spond.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.